Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Aging is being redefined as a treatable condition, not an inevitable decline. These companies are creating entirely new markets that could transform healthcare as we know it.
Recent clinical successes and scientific breakthroughs are accelerating investment in this space. The companies making meaningful progress now could become tomorrow's biotech giants.
These smaller biotechs represent a ground-floor opportunity in what could become a trillion-dollar industry addressing humanity's most universal concern: healthy aging.
Aging is being transformed from an inevitable process to a modifiable condition. These companies are at the forefront of developing technologies to extend healthspan—the period of life spent in good health—by targeting the root causes of aging rather than just treating symptoms.
This is a high-risk, high-reward investment theme. These clinical-stage biotechs are developing cutting-edge technologies like senolytics, cellular reprogramming, and gene editing. Success could mean revolutionary new treatments, but the path to regulatory approval is complex and uncertain.
Each company was selected for its dedicated focus on core aging pathways and progress in clinical development. Their work spans removing senescent cells, reprogramming cellular behavior, editing genes, and repairing DNA damage—all fundamental approaches to addressing aging at its biological roots.
Market capitalisation breakdown for the Age-Reversal Biotech basket.
UBX: $5.17M
LGVN: $17.67M
IPSC: $48.81M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
CENTURY THERAPEUTICS INC
IPSC
Current Price
$2.09
The company's platform is built on induced pluripotent stem cells (iPSCs), a cornerstone technology for cellular reprogramming and regenerative medici...
The company's platform is built on induced pluripotent stem cells (iPSCs), a cornerstone technology for cellular reprogramming and regenerative medicine.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+588.73%
On average, analysts expect assets in this group to grow 588.73% over the next year.
11 of 13 assets in this group are rated Buy by professional analysts.
